Status:
COMPLETED
A Study of Carbon-14-Labelled [14C] LY3871801 in Healthy Male Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to evaluate how much of the study drug (LY3871801), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into ...
Eligibility Criteria
Inclusion
- Male participants who are overtly healthy as determined by medical evaluation
- Have a body mass index of 18.5 to 32.0 kilograms per meter squared (kg/m²), inclusive
- Males who agree to use highly effective or effective methods of contraception
Exclusion
- Have known allergies to LY3871801, related compounds, or any components of the formulation, or a history of significant atopy
- Have received or intend to receive any vaccination within 30 days prior to dosing until the follow-up phone call
- Have participated in a radiolabeled drug study, where exposures are known to the investigator or designee, within 4 months prior to check-in, or participated in a radiolabeled drug study, where exposures are not known to the investigator or designee, within 6 months prior to check-in
Key Trial Info
Start Date :
September 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 3 2023
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT06049108
Start Date
September 15 2023
End Date
November 3 2023
Last Update
January 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Covance Clinical Research Unit
Madison, Wisconsin, United States, 53704